EU grants marketing authorization to Gilead for HIV-1 drug
Following the authorization, Eviplera will be made commercially available in all 27 countries of the European Union (EU). Eviplera combines Gilead’s Truvada, a fixed-dose combination of the two
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.